Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients

Suhail Nurbhai(VHsquared (United Kingdom)), Jenny Crowe(VHsquared (United Kingdom))
Scientific Reports
October 1, 2019
10.1038/s41598-019-50545-x
Cited by 38

Related Papers

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease
|Scientific Reports|2018|58
The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet-accelerated mouse model of ageing
|PLoS Pathogens|2020|38